Novavax Reports Q1 Net Loss Amid Revenue Decline, Boosted by Pfizer Deal & New $330M Credit Facility
NVAX sits 50% above its 52-week low of $5.8.
Summary
Novavax reported a net loss of $9.5 million in Q1 2026, a significant drop from the prior year, but secured a new $330 million credit facility and recognized a $30 million upfront payment from a Pfizer partnership for its Matrix-M adjuvant, affirming sufficient capital for the next 12 months.
Key Events · Earnings and Guidance · NVAX
-
Q1 Financial Performance
Novavax reported a net loss of $9.5 million for Q1 2026, a significant decline from a net income of $518.6 million in Q1 2025. Total revenue decreased to $139.5 million from $666.7 million in the prior year, primarily due to lower product sales and the absence of large APA termination revenues from Q1 2025.
-
Pfizer Partnership Initiated
The company recognized a $30 million upfront payment in Q1 2026 from a new License and Option Agreement with Pfizer (January 2026) for its Matrix-M adjuvant, with potential for up to $500 million in additional development and sales milestones, plus tiered high mid-single digit royalties.
-
New Credit Facility Secured
Novavax secured a senior secured term loan facility of up to $330 million with MidCap Financial Trust in February 2026, with $50 million funded at closing, increasing long-term debt to $291 million.
-
Liquidity and Going Concern Affirmation
The company affirmed it expects to have sufficient capital to fund operations for at least the next 12 months, with total cash, cash equivalents, restricted cash, and marketable securities at $794.9 million as of March 31, 2026.
Analysis · NVAX · Life Sciences
Novavax's Q1 2026 results show a significant year-over-year decline in revenue and a net loss, primarily due to the absence of large one-time APA termination benefits recognized in Q1 2025. However, the company made substantial strategic progress by recognizing a $30 million upfront payment from a new Pfizer partnership for its Matrix-M adjuvant, which also offers significant future milestone and royalty potential. The securing of a new $330 million credit facility, with $50 million funded, significantly bolsters liquidity and supports the company's going concern statement for the next 12 months. Investors should monitor the progress of these new partnerships and the impact of ongoing restructuring efforts on future profitability and cash flow.
At the time of this filing, NVAX was trading at $8.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.80 to $11.97. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.